Pan-Canadian overpricing of medicines: A 6-country study of cost control for generic medicines

Open Medicine

Volumn 8, Issue 4, 2014, Pages 130-135

  Beall, Reed F ^a   Nickerson, Jason W ^b   Attaran, Amir ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

^b BRUYÈRE RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GENERIC DRUG;

CANADA; COST; COST CONTROL; ECONOMICS; HEALTH; HUMAN; STATISTICS AND NUMERICAL DATA;

CANADA; COST CONTROL; COSTS AND COST ANALYSIS; DRUGS, GENERIC; GLOBAL HEALTH; HUMANS;

EID: 84919650991     PISSN: None     EISSN: 19112092     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Council of the Federation. Provinces and territories seek significant cost savings for Canadians on generic drugs [news release]. Ottawa (ON): Council of the Federation Secretariat; 2013. Available from: www.conseildelafederation.ca/en/latest-news/13-2013/122-territories-seek-significant-cost-savings-on-generic-drugs (accessed 2014 Aug 28).
2. Low Cost Alternative (LCA) and Reference Drug Program (RDP) data files. Victoria (BC): Government of British Columbia, Ministry of Health; 2013. Available from: www.health.gov.bc.ca/pharmacare/lca/lcabooklets.html (accessed 2014 Aug 28).
3. Lockwood C. Generic and branded prices in Canada: the provinces and territories band together in the cost-containment drive. In: IHS healthcare and pharma blog. Englewood (CO): IHS; 2013. Available from: http://healthcare.blogs.ihs.com/2013/03/14/generic-and-branded-prices-in-canada-the-provinces-and-territories-band-together-in-the-cost-containment-drive/(accessed 2014 Aug 28).
4. MacDonald K. Demystifying drug prices in Alberta. In: Benefits Canada [website]. Toronto (ON): Rogers Publishing Ltd.; 2013. Available from: www.benefitscanada.com/benefits/health-benefits/demystifying-drug-prices-in-alberta-40886 (accessed 2014 Aug 28).
5. Progress report 2013: health care renewal in Canada. Toronto (ON): Health Council of Canada; 2013. Available from: www.healthcouncilcanada.ca/rpt_det.php?id=481 (accessed 2014 Aug 28).
6. Progress report 2012: health care renewal in Canada. Toronto (ON): Health Council of Canada; 2012. Available from: www.healthcouncilcanada.ca/rpt_det.php?id=377 (accessed 2014 Aug 28).
7. Progress report 2011: health care renewal in Canada. Toronto (ON): Health Council of Canada; 2011. Available from: http://healthcouncilcanada.ca/rpt_det.php?id=165 (accessed 2014 Aug 28).
8. Bell C, Griller D, Lawson J, Lovren D. Generic drug pricing and access in Canada: What are the implications? Toronto (ON): Health Council of Canada; 2010. Available from: www.healthcouncilcanada.ca/rpt_det.php?id=156 (accessed 2014 Aug 28).
9. Patented Medicines Regulations, SOR/94-688, 1994. Available from: http://laws-lois.justice.gc.ca/eng/regulations/SOR-94-688/page-1.html (accessed 2014 Aug 28).
10. Morgan S, Hanley G, McMahon M, Barer M. Influencing drug prices through formulary-based policies: lessons from New Zealand. Healthc Policy 2007;3(1):e121-e140.
11. Law M. Money left on the table: generic drug prices in Canada. Healthc Policy 2013;8(3):17-25.
12. Generic drugs in Canada: international price comparisons and potential cost savings. Ottawa (ON): Patented Medicine Prices Review Board; 2011. Available from: www.pmprb-cepmb.gc.ca/CMFiles/Publications/Analytical%20Studies/NPDUIS-GenericDrugs-IPCs-e-sept30.pdf (accessed 2014 Sep 30).
13. Drug system reforms. Example: 4 generic drugs in 5 other countries. Toronto (ON): Ontario Ministry of Health and Long-term Care; 2008. Available from: www.health.gov.on.ca/en/public/programs/drugreforms/genericdrugs_chart.aspx (accessed 2014 Aug 28).
14. Appendix C: Bilateral price comparison at drug level. In: Analytical snapshot: international generic price comparison, early 2011. Ottawa (ON): Patented Medicine Prices Review Board; 2013. p. 13-14. Available from: www.pmprb-cepmb.gc.ca/CMFiles/NPDUIS/NPDUIS_ International_Price:Comparison_Snapshot_2013-08-28_EN.pdf (accessed 2014 Sep 14).'
15. Generic drug prices: a Canada US comparison. PDCI Report Series. Ottawa (ON): Palmer D'Angelo Consulting Inc.; 2002. Available from: www.pdci.on.ca/pdf/generic%20pricing%20study%20final%20 report.pdf (accessed 2014 Aug 28).
16. Generic drugs in Canada: a policy paper. Toronto (ON): Canadian Treatment Action Council; 2007. Available from: www.ctac.ca/uploads/Position%20Papers/2007%20EN_PP%20Generic_Drugs_ in_Canada_April_2007_FINAL.pdf (accessed 2014 Aug 28).
17. Benefiting from generic drug competition in Canada: the way forward. Gatineau (QC): Competition Bureau; 2008. Available from: www.competitionbureau.gc.ca/eic/site/cb-bc.nsf/eng/02753.html (accessed 2014 Aug 28).
18. Law MR, Kratzer J. The road to competitive generic drug prices in Canada. CMAJ 2013;185(13):1141-1144.
19. Law M, Ystma A, Morgan S. The short-term impact of Ontario's generic pricing reforms. PLoS One 2011;6(7):e23030.
20. Drugs funded by Ontario Drug Benefit (ODB) program. Toronto (ON): Ontario Ministry of Health and Long-term Care; 2013. Available from: www.health.gov.on.ca/en/pro/programs/drugs/odbf_mn.aspx (accessed 2014 Aug 28).
21. NHS Business Services Authority, NHS Prescription Services. Electronic drug tariff. London (UK): Department of Health, National Health Service England and Wales; 2014. Available from: www.ppa.org.uk/ppa/edt_intro.htm (accessed 2014 Oct 2).
22. Downloadcenter Arzneimittel-Festbeträge [Download Center for Fixed Drug Price Amounts] [website]. Deutsches Institut für Medizinische Dokumentation und Information [German Institute of Medical Documentation and Information]; 2013. Available from: www.dimdi.de/dynamic/de/amg/festbetraege-zuzahlung/festbetraege/downloadcenter/(accessed 2014 Aug 28).
23. Pharmaceutical prices [website]. Washington (DC): US Department of Veterans Affairs, Pharmacy Benefits Management Services; 2013. Available from: www.pbm.va.gov/PharmaceuticalPrices.asp (accessed 2014 Aug 28).
24. Profile of veterans: 2011. Data from the American Community Survey. Washington (DC): US Department of Veterans Affairs, National Center for Veterans Analysis and Statistics; 2013. Available from: www.va.gov/vetdata/docs/SpecialReports/Profile_of_Veterans_2011.pdf (accessed 2014 Sep 30).
25. Pharmaceutical schedule [website]. Wellington (New Zealand): PHARMAC Pharmaceutical Management Agency; 2013-2014. Available from: www.pharmac.health.nz/tools-resources/pharmaceutical-schedule (accessed 2014 Aug 28).
26. Läkemedel [Welcome to the TLV] [website]. Stockholm (Sweden): Tandvårds-Och Läkemedelsförmånsverket [Dental and Pharmaceutical Benefits Agency]. Available from: www.tlv.se/beslut/sok/lakemedel/(accessed 2014 Aug 28).
27. 10-year currency converter. Ottawa (ON): Bank of Canada. Available from: www.bankofcanada.ca/rates/exchange/10-year-converter/(accessed 2014 Aug 28).
28. Council of the Federation. From innovation to action: the first report of the Health Care Innovation Working Group. Ottawa (ON): Council of the Federation Secretariat; 2012. Available from: www.conseildelafederation.ca/en/featured-publications/75-council-of-thefederation- to-meet-in-victoria (accessed 2014 Aug 28).
29. Lunn S. Provinces reach deal to save on 6 generic drugs: Premiers say agreement will cut costs by $100M on common drugs. CBC News 2013 Jan 18. Available from: www.cbc.ca/news/politics/provinces-reach-deal-to-save-on-6-generic-drugs-1.1331370 (accessed 2014 Aug 28).
30. The Swedish pharmaceutical reimbursement system-a brief overview. Solna (Sweden): Pharmaceutical Benefits Board; 2007. Available from: www.tlv.se/Upload/English/ENG-swe-pharma -reimbursement-system.pdf (accessed 2014 Aug 28).
31. Hollis A, Grootendorst P. Tendering generic drugs: What are the risks? Toronto (ON): Canadian Generic Pharmaceutical Association; 2012. Available from: www.canadiangenerics.ca/en/advocacy/docs/10.24.12%20Tendering%20Generic%20Drugs%20-%20What%20Are%20the%20Risks_FINAL.pdf (accessed 2014 Aug 28).
32. Patented Medicines (Notice of Compliance) Regulations, SOR/93-133, 1993 [amended 2011 Mar 25]. Available from: http://laws-lois.justice. gc.ca/PDF/SOR-93-133.pdf (accessed 2014 Aug 28).
33. Hore E. A comparison of United States and Canadian laws as they affect generic pharmaceutical market entry. Food Drug Law J 2000;55(3):373-388.